Trial Profile
A Retrospective Chart Review Study of Monitoring for and Characterizing Crizotinib Progression In Patients With ALK-Positive Non-Small Cell Lung Cancer In A Real-World Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jun 2017 New trial record
- 03 Jun 2017 Results published in the Advances in Therapy